Differential Regulation of Hepatic Macrophage Fate by Chi3l1 in MASLD
Jia HeiD, Bo CheniD, Weiju Lu, Xiong WangiD, Ruoxue Yang, Chengxiang Deng, Xiane Zhu, Keqin Wang, L WangiD, Cheng XieiD, RC LiiD, Xiaokang Lu, Ruizhi Yang, Cheng PengiD, Canpeng Li, Zhao ShaniD
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) progression involves the replacement of protective embryo-derived Kupffer cells (KCs) by inflammatory monocyte-derived macrophages (MoMFs), yet the regulatory mechanisms remain unclear. Here, we identify chitinase 3-like 1 (Chi3l1/YKL-40) as a critical metabolic regulator of hepatic macrophage fate. We observed high expression of Chi3l1 in both KCs and MoMFs during MASLD development. Genetic deletion of Chi3l1 specifically in KCs significantly exacerbated MASLD severity and metabolic dysfunction, whereas MoMF-specific Chi3l1 deletion showed minimal metabolic effects. Mechanistic studies revealed that this cell type-specific regulation arises from differential metabolic requirements: KCs display elevated glucose metabolism compared to MoMFs. Chi3l1 directly interacts with glucose to inhibit its cellular uptake, thereby selectively protecting glucose-dependent KCs from metabolic stress-induced cell death while having negligible effects on less glucose-dependent MoMFs. These findings uncover a novel Chi3l1-mediated metabolic checkpoint that preferentially maintains KCs populations through glucose metabolism modulation, providing important new insights into the pathogenesis of MASLD and potential therapeutic strategies targeting macrophage-specific metabolic pathways.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 3
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Hyperactivated Glycolysis Drives Spatially-Patterned Kupffer Cell Depletion in MASLD
- Ablation of hepatocyte derived-FGL1 does not aggravate metabolic dysfunction-associated steatotic liver disease and hepatocellular carcinoma
Jean Personnaz, Lisa Cannizzo, … Léon Kautz·The FASEB JournalPeer-reviewed·Aug 20, 2025
- Induction of TFEB promotes Kupffer cell survival and reduces lipid accumulation and inflammation in MASLD
Mandy M. Chan, Sabine Daemen, … Joel D. Schilling·bioRxiv·Apr 19, 2025
- The ferroptosis mediator ACSL4 fails to prevent disease progression in mouse models of MASLD
Carolin Angendohr, Christiane Koppe, … Tom Luedde·Hepatology CommunicationsPeer-reviewed·May 16, 2025
- Non-Necroptotic Roles of MLKL in Diet-Induced Obesity, Liver Pathology, and Insulin Sensitivity: Insights from a High Fat, High Fructose, High Cholesterol Diet Mouse Model
P. Ohene-Marfo, H. V. M. Nguyen, … S. S. Deepa·bioRxiv·Jan 10, 2024
- ATF3 Preserves Macrophage Cholesterol Homeostasis during Metabolic Stress
Ty D Troutman, Amelia M Pearson, … Senad Divanovic·bioRxiv·Nov 9, 2026